IMMUNITYBIO, INC. (IBRX) Shareholder Equity
- 2026-06-30: Common Stock, Value, IssuedUSD $105.00K; Additional Paid in Capital, Common StockUSD $3.52B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $27.28M; Retained Earnings (Accumulated Deficit)USD $-4.59B.
- 2026-03-31: Common Stock, Value, IssuedUSD $104.00K; Additional Paid in Capital, Common StockUSD $3.46B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $27.45M; Retained Earnings (Accumulated Deficit)USD $-4.36B.
- 2025-12-31: Common Stock, Value, IssuedUSD $101.00K; Additional Paid in Capital, Common StockUSD $3.20B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $28.96M; Retained Earnings (Accumulated Deficit)USD $-3.73B.
- 2025-09-30: Common Stock, Value, IssuedUSD $98.00K; Additional Paid in Capital, Common StockUSD $3.14B; Accumulated Other Comprehensive Income (Loss), Net of TaxUSD $5.00M; Retained Earnings (Accumulated Deficit)USD $-3.66B.
IMMUNITYBIO, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Common Stock, Value, Issued USD | Additional Paid in Capital, Common Stock USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Adjustments to Additional Paid in Capital, Other USD | Noncontrolling Interest, Decrease from Deconsolidation USD | APIC, Share-based Payment Arrangement, Recognition and Exercise USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $105.00K | $3.52B | $27.28M | $-4.59B | $-1.05B | $-1.05B | 163.80K | 3 month · $8.52M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2026-03-31 | $104.00K | $3.46B | $27.45M | $-4.36B | $-870.01M | $-869.13M | 163.80K | 3 month · $8.17M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $101.00K | $3.20B | $28.96M | $-3.73B | $-500.47M | $-499.57M | 163.80K | 12 month · $36.81M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $98.00K | $3.14B | $5.00M | $-3.66B | $-524.32M | $-523.41M | 163.80K | 3 month · $8.88M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $91.00K | $3.01B | $12.57M | $-3.60B | $-570.75M | $-569.82M | 163.80K | 3 month · $9.65M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $85.00K | $2.89B | $19.96M | $-3.50B | $-591.43M | $-590.48M | 163.80K | 3 month · $9.54M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $85.00K | $2.88B | $1.20M | $-3.38B | $-489.10M | $-488.13M | 163.80K | 12 month · $34.43M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $70.00K | $2.57B | $103.00K | $-3.32B | $-745.15M | $-744.16M | 163.80K | 3 month · $7.49M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $69.00K | $2.53B | $-8.00K | $-3.23B | $-698.39M | $-697.38M | 163.80K | 3 month · $9.64M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $68.00K | $2.40B | $-7.00K | $-3.10B | $-692.01M | $-690.98M | 163.80K | 3 month · $8.27M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $67.00K | $2.37B | $10.00K | $-2.96B | $-586.99M | $-585.94M | 163.80K | 12 month · $49.16M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $67.00K | $2.32B | $792.00K | $-2.73B | $-411.72M | $-410.64M | 163.80K | 3 month · $14.45M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $44.00K | $1.99B | $-40.00K | $-2.63B | $-642.12M | $-645.18M | 163.80K | 3 month · $11.06M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $43.00K | $1.97B | $-33.00K | $-2.49B | $-528.98M | $-531.72M | 163.80K | 3 month · $10.88M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $42.00K | $1.93B | $183.00K | $-2.38B | $-447.33M | $-449.82M | 163.80K | 12 month · $40.18M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $40.00K | $1.84B | $-190.00K | $-2.27B | $-426.70M | $-429.08M | 163.80K | 3 month · $10.63M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $40.00K | $1.74B | $-110.00K | $-2.16B | $-419.81M | $-421.97M | 163.80K | 3 month · $10.18M 6 month · $20.20M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | $40.00K | $1.73B | $-367.00K | $-2.06B | $-335.64M | $-337.56M | 163.80K | 3 month · $10.02M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $40.00K | $1.72B | $4.00K | $-1.96B | $-242.17M | $-243.91M | 163.80K | 12 month · $57.18M | (m) | (m) | 12 month · $1.44M | (m) | (m) | (m) |
| 2021-09-30 | $39.00K | $1.68B | $53.00K | $-1.87B | $-188.50M | $-189.94M | 163.80K | 3 month · $13.84M 9 month · $47.00M | (m) | (m) | 3 month · $1.44M 9 month · $1.44M | (m) | (m) | (m) |
| 2021-06-30 | $39.00K | $1.63B | $37.00K | $-1.78B | $-157.94M | $-158.59M | (m) | 3 month · $17.86M 6 month · $33.16M | 3 month · $3.08M 6 month · $3.08M | (m) | (m) | (m) | (m) | 163.80K |
| 2021-03-31 | $38.00K | $1.51B | $-38.00K | $-1.69B | $-185.79M | $-185.34M | (m) | 3 month · $15.30M | (m) | (m) | (m) | (m) | (m) | 163.80K |
| 2020-12-31 | $38.00K | $1.50B | $122.00K | $-1.62B | $-119.81M | $-118.49M | 163.80K | 12 month · $2.19M | (m) | (m) | (m) | (m) | (m) | 163.80K |
| 2020-09-30 | $11.00K | $871.17M | $-117.00K | $-722.44M | $148.62M | $-51.07M | (m) | 3 month · $714.00K 9 month · $1.52M | 3 month · $4.37M 9 month · $4.37M | (m) | (m) | (m) | 3 month · $-321.00K 9 month · $-485.00K | (m) |
| 2020-06-30 | $11.00K | $870.41M | $-100.00K | $-700.67M | $169.65M | $14.38M | (m) | 3 month · $322.00K 6 month · $802.00K | 3 month · $4.39M 6 month · $4.39M | (m) | (m) | (m) | 3 month · $-40.00K 6 month · $-163.00K | (m) |
| 2020-03-31 | $10.00K | $783.29M | $-128.00K | $-680.57M | $102.59M | $-20.70M | (m) | 3 month · $480.00K | (m) | (m) | (m) | (m) | 3 month · $-123.00K | (m) |
| 2019-12-31 | $37.00K | $1.41B | $-87.00K | $-1.39B | $16.33M | $16.33M | (m) | 12 month · $3.42M | (m) | (m) | (m) | 12 month · $18.35M | (m) | 163.80K |
| 2019-09-30 | $10.00K | $782.55M | $-53.00K | $-646.55M | $135.96M | (m) | (m) | 3 month · $277.00K 9 month · $2.15M | (m) | (m) | (m) | (m) | 3 month · $-40.00K 9 month · $-66.00K | (m) |
| 2019-06-30 | $10.00K | $782.31M | $-84.00K | $-630.97M | $151.27M | (m) | (m) | 3 month · $522.00K 6 month · $1.87M | (m) | (m) | (m) | (m) | 3 month · $0.00 6 month · $-26.00K | (m) |
| 2019-03-31 | $10.00K | $781.79M | $-206.00K | $-613.79M | $167.81M | (m) | (m) | 3 month · $1.35M | (m) | (m) | (m) | (m) | 3 month · $-26.00K | (m) |
| 2018-12-31 | $8.00K | $741.25M | $-267.00K | $-594.98M | $81.94M | $81.94M | (m) | 12 month · $23.38M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2018-09-30 | $8.00K | $739.84M | $-348.00K | $-577.41M | $162.09M | (m) | (m) | 3 month · $3.97M 9 month · $21.98M | (m) | (m) | (m) | (m) | 9 month · $-123.00K | (m) |
| 2018-06-30 | $8.00K | $735.85M | $-448.00K | $-553.78M | $181.63M | (m) | (m) | 3 month · $8.93M 6 month · $18.01M | (m) | (m) | (m) | (m) | 6 month · $-123.00K | (m) |
| 2018-03-31 | $8.00K | $726.95M | $-555.00K | $-526.05M | $200.36M | (m) | (m) | 3 month · $9.07M | (m) | (m) | (m) | (m) | 3 month · $-73.00K | (m) |
| 2017-12-31 | $8.00K | $717.93M | $-381.00K | $-498.71M | $218.84M | (m) | (m) | 12 month · $37.00M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2017-09-30 | $8.00K | $709.35M | $-202.00K | $-471.45M | $237.70M | (m) | (m) | 9 month · $28.11M | (m) | (m) | (m) | (m) | 9 month · $-709.00K | (m) |
| 2017-06-30 | $8.00K | $700.64M | $-237.00K | $-447.49M | $252.92M | (m) | (m) | 6 month · $19.40M | (m) | (m) | (m) | (m) | 6 month · $-709.00K | (m) |
| 2017-03-31 | $8.00K | $691.23M | $-240.00K | $-412.63M | $278.37M | (m) | (m) | 3 month · $10.02M | (m) | (m) | (m) | (m) | 3 month · $-700.00K | (m) |
| 2016-12-31 | $8.00K | $680.76M | $-284.00K | $-387.06M | $293.42M | (m) | (m) | 12 month · $73.85M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-09-30 | $8.00K | $669.62M | $135.00K | $-358.88M | $310.89M | (m) | (m) | 9 month · $62.59M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | $8.00K | $651.33M | $424.00K | $-324.40M | $327.36M | (m) | (m) | 6 month · $43.92M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | $8.00K | $625.20M | $318.00K | $-281.03M | $344.50M | (m) | (m) | 3 month · $20.54M | (m) | (m) | (m) | (m) | (m) | (m) |
| 2016-01-01 | (m) | (m) | (m) | $31.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | $8.00K | $606.55M | $-192.00K | $-250.38M | $356.00M | (m) | (m) | 12 month · $211.22M | (m) | 12 month · $5.17M | (m) | (m) | (m) | (m) |
| 2015-09-30 | $8.00K | $535.70M | $-50.00K | $-172.72M | $362.93M | (m) | (m) | 9 month · $140.67M | (m) | 9 month · $5.17M | (m) | (m) | (m) | (m) |
| 2015-06-30 | $7.00K | $256.51M | (m) | $-130.00M | $126.52M | (m) | (m) | 6 month · $104.56M | (m) | 6 month · $5.17M | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $71.16M | (m) | $-12.74M | $57.59M | (m) | (m) | 12 month · $562.00K | (m) | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | (m) | (m) | (m) | (m) | $-3.75M | (m) | (m) | 12 month · $884.00K | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 |